Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
May 22, 2024
Read MoreZai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
May 20, 2024
Read MoreZai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
May 14, 2024
Read MoreZai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
May 12, 2024
Read MoreZai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
May 08, 2024
Read MoreZai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
Apr 15, 2024
Read MoreZai Lab Statement on Executive Management Team’s Agreement on Share Activities
Apr 11, 2024
Read More